Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
770.010.12%
QQQ
718.760.37%
BTC/USD
69790.290.7063%
DIA
534.640.07%
GLD
413.790.01%
TLT
82.990.04%

COLOPLAST AS SP/ADR by Coloplast AS

CLPBYOTCPK
Trade with Public
Trade with Public
$6.98
0.192.8%
At close: Aug 19, 5:00 PM EST
$6.98
N/A
After Hours: 4:09 PM EST
Earnings: Q3 2026 Earnings were released on Tue Aug 18th, before the market open
Conference Call: The most recent conference call started at 5:00 AM, 2 days ago
Click to view the webcast
OverviewNewsEarnings ForecastFinancialsSentimentOwnershipCompare

COLOPLAST AS SP/ADR by Coloplast AS Financials

COLOPLAST AS SP/ADR by Coloplast AS (CLPBY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Coloplast Affirms FY2026 Sales Guidance of $4.499B vs $4.420B Est

Coloplast (OTC:CLPBY) affirms FY2026 sales outlook from $4.499 billion to $4.499 billion vs $4.420 billion estimate.
Benzinga Newsdesk

PRO
Coloplast Q3 Adj. EPS $0.10, Inline, Sales $1.144B Beat $1.120B Estimate

Coloplast (OTC:CLPBY) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 66.67 percent increase over earnings of $0.06 per share from the same period last year. The
Benzinga Newsdesk

PRO
Coloplast Raises FY2026 Sales Guidance from $4.541B to $4.587B-$4.630B vs $4.540B Est

Coloplast (OTC:CLPBY) raises FY2026 sales outlook from $4.541 billion to $4.587 billion-$4.630 billion vs $4.540 billion estimate.
Benzinga Newsdesk

PRO
Coloplast Q2 Adj. EPS $0.10 Beats $0.09 Estimate, Sales $1.110B Beat $1.100B Estimate

Coloplast (OTC:CLPBY) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.09 by 11.11 percent. This is a 66.67 percent increase over earnings of $0.06 per share from the same
Benzinga Newsdesk

PRO
Coloplast Narrows FY2026 Sales Guidance from $4.541B-$4.585B to $4.541B; Sees ~4% YoY Revenue Growth

Coloplast (OTC:CLPBY) narrows FY2026 sales outlook from $4.541 billion-$4.585 billion to $4.541 billion.
Benzinga Newsdesk

PRO
Coloplast Q1 Adj. EPS $0.09, Inline, Sales $1.098B Up From $1.005B YoY

Coloplast (OTC:CLPBY) reported quarterly earnings of $0.09 per share which met the analyst consensus estimate. This is a 28.57 percent increase over earnings of $0.07 per share from the same period last year. The
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved